Generex Oncology Granted United States Patent for AE37 Peptide Vaccine
- Category: Vaccines
- Published on Tuesday, 13 July 2010 03:00
- Hits: 1169
Antigen Express has been granted a United States patent on AE37, its lead immunotherapeutic vaccine
WORCESTER, MA, USA | July 13, 2010 | Generex Biotechnology Corporation (www.generex.com) (Nasdaq:GNBT - News) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the first "composition of matter" patent to be issued relating to one of their development products.
The AE37 immunotherapeutic vaccine is being developed by Antigen Express, Generex's wholly-owned subsidiary, for use in patients with HER2 positive cancers:
* The vaccine is the subject of a randomized and controlled Phase II trial in patients with breast cancer; positive interim results, showing reduced relapse rates in patients receiving AE37, were released late in 2009.
* A Phase I trial of AE37 in patients with prostate cancer has been completed recently.
* A Phase I trial of AE37 in combination with another peptide vaccine is underway in patients with breast or ovarian cancer.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, buccal insulin (Generex Oral-lyn(TM)), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
SOURCE: Generex Biotechnology Corp.